ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck and CureVac strike Ivy League deals

by Ryan Cross
August 24, 2019 | APPEARED IN VOLUME 97, ISSUE 33

 

09733-buscon14-sharpecxd.jpg
Credit: Harvard Medical School
Harvard Medical School's Arlene Sharpe

Merck & Co. is providing Harvard Medical School professor Arlene Sharpe with an undisclosed amount of research funding for 4 years. Sharpe, who is chair of the Department of Immunology, helped discover the function of PD-1, a protein that is targeted by checkpoint inhibitor cancer therapies, including Merck’s Keytruda. Merck hopes to discover new immunotherapy drug targets. Separately, the German messenger-RNA-therapy company CureVac signed an agreement with Yale University pulmonologist Geoffrey Chupp to conduct preclinical research on mRNA therapies for lung diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment